A retrospective study from the European Group for Blood and Marrow Transplantation showed increased incidence of grades II–IV acute GVHD and chronic GVHD with G‐CSF administration among BMT patients, but not PBSCT patients.7 Here, CSF3 is linked to acute graft versus host disease.